Advanced search
Publication Cover
Future Microbiology Volume 5, 2010 - Issue 9
Submit an article Journal homepage
215
Views
0
CrossRef citations to date
0
Altmetric
Review

Third-Generation Smallpox Vaccines: Challenges in the Absence of Clinical Smallpox

Clement A Meseda1 Division of Viral Products,Center for Biologics Evaluation & Research,USFDA,1401 Rockville Pike, HFM-457,Rockville,MD 20852,USACorrespondence[email protected]
&
Jerry P Weir1 Division of Viral Products,Center for Biologics Evaluation & Research,USFDA,1401 Rockville Pike, HFM-457,Rockville,MD 20852,USA
Pages 1367-1382 | Published online: 22 Sep 2010

Bibliography

  • Fenner F , HendersonDA, AritaI, JezekZ, LadnyiID(Eds) : Smallpox and its Eradication. World Health Organization Geneva,Switzerland (1988).
  • Davidovitch N , GreenbergZ: Public health, culture, and colonial medicine: smallpox and variolation in Palestine during the British Mandate.Public Health Rep.122(3) , 398–406 (2007).
  • Dinc G , UlmanYI: The introduction of variolation ‘A La Turca‘ to the West by Lady Mary Montagu and Turkey‘s contribution to this.Vaccine25(21) , 4261–4265 (2007).
  • Jannetta A : Jennerian vaccination and the creation of a national public health agenda in Japan, 1850–1900.Bull. Hist. Med.83(1) , 125–140 (2009).
  • Mark C , Rigau-PerezJG: The world‘s first immunization campaign: the Spanish Smallpox Vaccine Expedition, 1803–1813.Bull. Hist. Med.83(1) , 63–94 (2009).
  • Breman JG , HendersonDA: Diagnosis and management of smallpox.N. Engl. J. Med.346(17) , 1300–1308 (2002).
  • CDC: Public Health Service recommendations on smallpox vaccination. Morb. Mortal. Wkl. Rep. 20 , 339 (1971).
  • Ladnyi ID , BremanJG: Smallpox eradication: progress and problems.Dev. Biol. Stand.41 , 281–290 (1978).
  • Institute of Medicine: Live Variola Virus: Considerations for Continuing Research. The National Academies Press, Washington, DC, USA (2009).
  • Moussatche N , DamasoCR, McFadden: When good vaccines go wild: feral orthopoxvirus in developing countries and beyond.J. Infect. Dev. Ctries2(3) , 156–173 (2008).
  • Levine RS , PetersonAT, YoritaKL, CarrollD, DamonIK, ReynoldsMG: Ecological niche and geographic distribution of human monkeypox in Africa.PLoS One2(1) , e176 (2007).
  • Meyer H , PerrichotM, StemmlerMet al. : Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001.J. Clin. Microbiol.40(8) , 2919–2921 (2002).
  • Heymann DL , SzczeniowskiM, EstevesK: Re-emergence of monkeypox in Africa: a review of the past six years.Br. Med. Bull.54(3) , 693–702 (1998).
  • CDC: Human monkeypox – Kasai Oriental, Zaire, 1996–1997. Morb. Mortal. Wkl. Rep. 46(14) , 304–307 (1997)
  • Breman JG , KalisaR, SteniowskiMV, ZanottoE, GromykoAI, AritaI: Human monkeypox, 1970–79.Bull. World Health Organ.58(2) , 165–182 (1980).
  • Trindade GS , LobatoZI, DrumondBPet al. : Short report: isolation of two vaccinia virus strains from a single bovine vaccinia outbreak in rural area from Brazil: implications on the emergence of zoonotic orthopoxviruses.Am. J. Trop. Med. Hyg.75(3) , 486–490 (2006).
  • Silva-Fernandes AT , TravassosCE, FerreiraJMet al. : Natural human infections with vaccinia virus during bovine vaccinia outbreaks.J. Clin. Virol.44(4) , 308–313 (2009).
  • Yadav S , HosamaniM, BalamuruganV, BhanuprakashV, SinghRK: Partial genetic characterization of viruses isolated from pox-like infection in cattle and buffaloes: evidence of buffalo pox virus circulation in Indian cows.Arch. Virol.155(2) , 255–261 (2010).
  • Nitsche A , PauliG: Sporadic human cases of cowpox in Germany.Euro. Surveill.12(4) , e070419 3 (2007).
  • Pelkonen PM , TarvainenK, HynninenAet al. : Cowpox with severe generalized eruption, Finland.Emerg. Infect. Dis.9(11) , 1458–1461 (2003).
  • Vorou RM , PapavassiliouVG, PierroutsakosIN: Cowpox virus infection: an emerging health threat.Curr. Opin. Infect. Dis.21(2) , 153–156 (2008).
  • Reed KD , MelskiJW, GrahamMBet al. : The detection of monkeypox in humans in the Western Hemisphere.N. Engl. J. Med.350(4) , 342–350 (2004).
  • CDC: Multistate outbreak of monkeypox – Illinois, Indiana, and Wisconsin. Morb. Mortal. Wkl. Rep. 52(23) , 537–540 (2003)
  • Lane JM , RubenFL, NeffJM, MillarJD: Complications of smallpox vaccination, 1968: results of ten statewide surveys.J. Infect. Dis.122(4) , 303–309 (1970).
  • Redfield RR , WrightDC, JamesWD, JonesTS, BrownC, BurkeDS: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease.N. Engl. J. Med.316(11) , 673–676 (1987).
  • Kempe CH , FulginitiV, MinamitaniM, ShinefieldH: Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78).Pediatrics42(6) , 980–985 (1968).
  • Vora S , DamonI, FulginitiVet al. : Severe eczema vaccinatum in a household contact of a smallpox vaccinee.Clin. Infect. Dis.46(10) , 1555–1561 (2008).
  • Arness MK , EckartRE, LoveSSet al. : Myopericarditis following smallpox vaccination.Am. J. Epidemiol.160(7) , 642–651 (2004).
  • Mora LF , KhanAH, SperlingLS: Cardiac complications after smallpox vaccination.South Med. J. (2009) (Epub ahead of print).
  • Van Dam CN , SyedS, EronJJet al. : Severe postvaccinia encephalitis with acute disseminated encephalomyelitis: recovery with early intravenous immunoglobulin, high-dose steroids, and vaccinia immunoglobulin.Clin. Infect. Dis.48(4) , E47–E49 (2009).
  • Bryant-Genevier M , O‘ConnellK, BallR, BraunMM, McMahonA: Passive surveillance for generalized vaccinia in the United States using the Vaccine Adverse Event Reporting System (VAERS).Vaccine24(17) , 3632–3635 (2006).
  • Halsell JS , RiddleJR, AtwoodJEet al. : Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel.JAMA289(24) , 3283–3289 (2003).
  • Eckart RE , ShryEA, JonesSOIV , AtwoodJE, GrabensteinJD: Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age.Am. J. Cardiol.95(10) , 1252–1255 (2005).
  • Jacobson IG , SmithTC, SmithB, WellsTS, ReedRJ, RyanMA: US military service members vaccinated against smallpox in 2003 and 2004 experience a slightly higher risk of hospitalization postvaccination.Vaccine26(32) , 4048–4056 (2008).
  • Rivers TM : Cultivation of vaccine virus for Jennerian prophylaxis in man.J. Exp. Med.54(4) , 453–461 (1931).
  • Mayr A , SticklH, MullerHK, DannerK, SingerH: The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism [author‘s translation].Zentralbl. Bakteriol. B167(5–6) , 375–390 (1978).
  • Hashizume S , YoshizawaH, MoritaM, SuzukiK: Properties of attenuated mutant of vaccinia virus LC16m8, derived from Lister strain.In: Vaccinia Viruses as Vectors for Vaccine Antigens.Quinnan (Ed.) , Elsevier Science Publishing Co.,NY, USA87–99 (1985).
  • Kennedy RB , OvsyannikovaIG, JacobsonRM, PolandGA: The immunology of smallpox vaccines.Curr. Opin. Immunol.21(3) , 314–320 (2009).
  • Paran N , SutterG: Smallpox vaccines: new formulations and revised strategies for vaccination.Hum. Vaccin.5(12) , 824–831 (2009).
  • Jacobs BL , LanglandJO, KiblerKVet al. : Vaccinia virus vaccines: past present and future.Antiviral Res.84(1) , 1–13 (2009).
  • Weltzin R , LiuJ, PugachevKVet al. : Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.Nat. Med.9(9) , 1125–1130 (2003).
  • Greenberg RN , KennedyJS: ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine.Expert Opin. Invest. Drugs17(4) , 555–564 (2008).
  • Monath TP , CaldwellJR, MundtWet al. : ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense.Int. J. Infect. Dis. Suppl.2 , S31–S44 (2004).
  • Weber HG : Utilization of the MVA-immunization schedule from the view point of the public health service.Fortschr. Med.95(21) , 1381–1386 (1977).
  • Cosma A , NagarajR, StaibCet al. : Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.AIDS Res. Hum. Retroviruses23(6) , 782–793 (2007).
  • Kretzschmar M , WallingaJ, TeunisP, XingS, MikolajczykR: Frequency of adverse events after vaccination with different vaccinia strains.PLoS Med.3(8) , E272 (2006).
  • Kenner J , CameronF, EmpigC, JobesDV, GurwithM: LC16m8: an attenuated smallpox vaccine.Vaccine24(47–48) , 7009–7022 (2006).
  • Tartaglia J , PerkusME, TaylorJet al. : NYVAC: a highly attenuated strain of vaccinia virus.Virology188(1) , 217–232 (1992).
  • Coulibaly S , BruhlP, MayrhoferJ, SchmidK, GerencerM, FalknerFG: The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.Virology341(1) , 91–101 (2005)
  • Jentarra GM , HeckMC, YounJWet al. : Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination.Vaccine26(23) , 2860–2872 (2008).
  • Earl PL , AmericoJL, WyattLSet al. : Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.Nature428(6979) , 182–185 (2004)
  • Meseda CA , GarciaAD, KumarAet al. : Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.Virology339(2) , 164–175 (2005).
  • Earl PL , AmericoJL, WyattLSet al. : Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.Proc. Natl Acad. Sci. USA105(31) , 10889–10894 (2008).
  • Midgley CM , PutzMM, WeberJN, SmithGL: Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.J. Gen. Virol.89(Pt 12) , 2992–2997 (2008).
  • He Y , ManischewitzJ, MesedaCAet al. : Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine – induced immunity.J. Infect. Dis.196(7) , 1026–1032 (2007).
  • Fogg CN , AmericoJL, EarlPLet al. : Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.J. Virol.82(16) , 8022–8029 (2008).
  • Saito T , FujiiT, KanataniYet al. : Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8.JAMA301(10) , 1025–1033 (2009).
  • Wilck MB , SeamanMS, BadenLRet al. : Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.J. Infect. Dis.201(9) , 1361–1370 (2010).
  • Seaman MS , WilckMB, BadenLRet al. : Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.J. Infect. Dis.201(9) , 1353–1360 (2010).
  • Tine JA , LanarDE, SmithDMet al. : NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.Infect. Immun.64(9) , 3833–3844 (1996).
  • Esteban M : Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.Hum. Vaccin.5(12) , 867–871 (2009).
  • Weyer J , RupprechtCE, NelLH: Poxvirus-vectored vaccines for rabies – a review.Vaccine27(51) , 7198–7201 (2009).
  • Meseda CA , MayerAE, KumarAet al. : Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.Clin. Vaccine Immunol.16(9) , 1261–1271 (2009).
  • Stabenow J , BullerRM, SchriewerJ, WestC, SagartzJE, ParkerS: A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.J. Virol.84(8) , 3909–3920 (2010).
  • Garza NL , HatkinJM, LivingstonVet al. : Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.Vaccine27(40) , 5496–5504 (2009).
  • Stittelaar KJ , van AmerongenG, KondovaIet al.: Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.J. Virol.79(12) , 7845–7851 (2005).
  • Saijo M , AmiY, SuzakiYet al. : LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox.J. Virol.80(11) , 5179–5188 (2006).
  • Empig C , KennerJR, Perret-GentilMet al. : Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.Vaccine24(17) , 3686–3694 (2006).
  • Hammarlund E , LewisMW, HansenSGet al. : Duration of antiviral immunity after smallpox vaccination.Nat. Med.9(9) , 1131–1137 (2003).
  • Lai CF , GongSC, EstebanM: The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals.J. Virol.65(10) , 5631–5635 (1991).
  • Galmiche MC , GoenagaJ, WittekR, RindisbacherL: Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.Virology254(1) , 71–80 (1999).
  • Fogg C , LustigS, WhitbeckJC, EisenbergRJ, CohenGH, MossB: Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.J. Virol.78(19) , 10230–10237 (2004).
  • Davies DH , McCauslandMM, ValdezCet al. : Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.J. Virol.79(18) , 11724–11733 (2005).
  • Sakhatskyy P , WangS, ChouTH, LuS: Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen.Virology355(2) , 164–174 (2006).
  • Benhnia MR , McCauslandMM, SuHPet al. : Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.J. Virol.82(7) , 3751–3768 (2008).
  • Nelson GE , SislerJR, ChandranD, MossB: Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies.Virology380(2) , 394–401 (2008).
  • Sirven P , CastelliFA, ProbstA, SzelyN, MaillereB: In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R.Mol. Immunol.46(7) , 1481–1487 (2009).
  • Smith GL , VanderplasschenA, LawM: The formation and function of extracellular enveloped vaccinia virus.J. Gen. Virol.83(Pt 12) , 2915–2931 (2002).
  • Roberts KL , SmithGL: Vaccinia virus morphogenesis and dissemination.Trends Microbiol.16(10) , 472–479 (2008).
  • Condit RC , MoussatcheN, TraktmanP: In a nutshell: structure and assembly of the vaccinia virion.Adv. Virus Res.66 , 31–124 (2006).
  • Appleyard G , HapelAJ, BoulterEA: An antigenic difference between intracellular and extracellular rabbitpox virus.J. Gen. Virol.13(1) , 9–17 (1971).
  • Boulter EA , ZwartouwHT, TitmussDH, MaberHB: The nature of the immune state produced by inactivated vaccinia virus in rabbits.Am. J. Epidemiol.94(6) , 612–620 (1971).
  • Sette A , GreyH, OseroffCet al. : Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens.Vaccine27(Suppl. 6) , G21–G26 (2009).
  • Moutaftsi M , TscharkeDC, VaughanKet al. : Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens.Future Microbiol.5(2) , 221–239 (2010).
  • McIntosh K , CherryJD, BenensonASet al. : Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Standard percutaneous revaccination of children who receive primary percutaneous vaccination.J. Infect. Dis.135(1) , 155–166 (1977).
  • Mack TM , NobleJJr , ThomasDB: A prospective study of serum antibody and protection against smallpox.Am. J. Trop. Med. Hyg.21(2) , 214–218 (1972).
  • Fenner F : Studies in infectious ectromelia of mice; immunization of mice against ectromelia with living vaccinia virus.Aust. J. Exp. Biol. Med. Sci.25(Pt 3) , 257–274 (1947).
  • Kempe CH , BowlesC, MeiklejohnGet al. : The use of vaccinia hyperimmune g-globulin in the prophylaxis of smallpox.Bull. World Health Organ.25 , 41–48 (1961).
  • Goldstein JA , NeffJM, LaneJM, KoplanJP: Smallpox vaccination reactions, prophylaxis, and therapy of complications.Pediatrics55(3) , 342–347 (1975).
  • Lustig S , Maik-RachlineG, ParanNet al. : Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response.Vaccine27(11) , 1691–1699 (2009).
  • Edghill-Smith Y , GoldingH, ManischewitzJet al. : Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.Nat. Med.11(7) , 740–747 (2005).
  • Chaudhri G , PanchanathanV, BluethmannH, KarupiahG: Obligatory requirement for antibody in recovery from a primary poxvirus infection.J. Virol.80(13) , 6339–6344 (2006).
  • Panchanathan V , ChaudhriG, KarupiahG: Antiviral protection following immunization correlates with humoral but not cell-mediated immunity.Immunol. Cell Biol.88(4) , 461–467 (2010).
  • Karupiah G , XieQW, BullerRM, NathanC, DuarteC, MacMickingJD: Inhibition of viral replication by interferon-γ-induced nitric oxide synthase.Science261(5127) , 1445–1448 (1993).
  • Karupiah G , BullerRM, Van RooijenN, DuarteCJ, ChenJ: Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection.J. Virol.70(12) , 8301–8309 (1996).
  • Chaudhri G , PanchanathanV, BullerRMet al. : Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox.Proc. Natl Acad. Sci. USA101(24) , 9057–9062 (2004).
  • Panchanathan V , ChaudhriG, KarupiahG: Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.J. Virol.80(13) , 6333–6338 (2006).
  • Senkevich TG , WardBM, MossB: Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene.J. Virol.78(5) , 2357–2366 (2004).
  • Senkevich TG , OjedaS, TownsleyA, NelsonGE, MossB: Poxvirus multiprotein entry-fusion complex.Proc. Natl Acad. Sci. USA102(51) , 18572–18577 (2005).
  • Fang M , ChengH, DaiZ, BuZ, SigalLJ: Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.Virology345(1) , 231–243 (2006)
  • Hooper JW , ThompsonE, WilhelmsenCet al. : Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.J. Virol.78(9) , 4433–4443 (2004).
  • Golden JW , HooperJW: Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine.Virology377(1) , 19–29 (2008).
  • Aldaz-Carroll L , WhitbeckJC, Ponce deLeon Met al.: Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.J. Virol.79(10) , 6260–6271 (2005).
  • Barefoot B , ThornburgNJ, BarouchDHet al. : Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.Vaccine26(48) , 6108–6118 (2008).
  • Hooper JW , FerroAM, GoldenJWet al. : Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.Vaccine28(2) , 494–511 (2009).
  • O‘Connell CJ , KarzonDT, BarronAL, PlautME, AliVM: Progressive vaccinia with normal antibodies. A case possibly due to deficient cellular immunity.Ann. Intern. Med.60 , 282–289 (1964).
  • Blanden RV : Mechanisms of recovery from a generalized viral infection: mousepox. II. Passive transfer of recovery mechanisms with immune lymphoid cells.J. Exp. Med.133(5) , 1074–1089 (1971).
  • Mullbacher A , LobigsM, YewdellJW, BenninkJR, Tha HlaR, BlandenRV: High peptide affinity for MHC class I does not correlate with immunodominance.Scand. J. Immunol.50(4) , 420–426 (1999).
  • Ennis FA , CruzJ, DemkowiczWEJr , RothmanAL, McClainDJ: Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-g-producing T cells after smallpox vaccination.J. Infect. Dis.185(11) , 1657–1659 (2002).
  • Kim SH , YeoSG, ChoJHet al. : Cell-mediated immune responses to smallpox vaccination.Clin. Vaccine Immunol.13(10) , 1172–1174 (2006).
  • Dong Y , DennyTN: HLA-A2-restricted human CD8+ cytotoxic T lymphocyte responses to a novel epitope in vaccinia virus that is conserved among orthopox viruses.J. Infect. Dis.194(2) , 168–175 (2006).
  • Terajima M , CruzJ, RainesGet al. : Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses.J. Exp. Med.197(7) , 927–932 (2003).
  • Flesch IE , WooWP, WangYet al. : Altered CD8+ T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F(1) mice.J. Immunol.184(1) , 45–55 (2010).
  • Tscharke DC , KarupiahG, ZhouJet al. : Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines.J. Exp. Med.201(1) , 95–104 (2005).
  • Doherty PC , BiddisonWE, BenninkJR, KnowlesBB: Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype.J. Exp. Med.148(2) , 534–543 (1978).
  • Phelps A , GatesAJ, HillierM, EastaughL, UlaetoDO: Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model.Vaccine23(27) , 3500–3507 (2005).
  • Kaufman DR , GoudsmitJ, HoltermanLet al. : Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.J. Virol.82(14) , 6829–6837 (2008).
  • Yu W , FangQ, ZhuWet al. : One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge.Vaccine28(9) , 2088–2096 (2010).
  • Rock MT , YoderSM, TalbotTR, EdwardsKM, CroweJEJr : Cellular immune responses to diluted and undiluted aventis pasteur smallpox vaccine.J. Infect. Dis.194(4) , 435–443 (2006).
  • Frey SE , NewmanFK, KennedyJSet al. : Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.Vaccine27(10) , 1637–1644 (2009).
  • Luttge BG , MoyerRW: Suppressors of a host range mutation in the rabbitpox virus serpin SPI-1 map to proteins essential for viral DNA replication.J. Virol.79(14) , 9168–9179 (2005).
  • Roper RL , WolffeEJ, WeisbergA, MossB: The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus.J. Virol.72(5) , 4192–4204 (1998).
  • Hooper JW , GoldenJW, FerroAM, KingAD: Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge.Vaccine25(10) , 1814–1823 (2007).
  • Heraud JM , Edghill-SmithY, AyalaVet al. : Subunit recombinant vaccine protects against monkeypox.J. Immunol.177(4) , 2552–2564 (2006).
  • Putz MM , MidgleyCM, LawM, SmithGL: Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination.Nat. Med.12(11) , 1310–1315 (2006).
  • Hooper JW , CusterDM, SchmaljohnCS, SchmaljohnAL: DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.Virology266(2) , 329–339 (2000).
  • Hooper JW , CusterDM, ThompsonE: Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.Virology306(1) , 181–195 (2003).
  • Trojan A , RajeswaranR, MontemurroM, MutschM, SteffenR. Real time PCR for the assessment of CD8+ T cellular immune response after prophylactic vaccinia vaccination.J. Clin. Virol.40(1) , 80–83 (2007).
  • Davies DH , WyattLS, NewmanFKet al. : Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.J. Virol.82(2) , 652–663 (2008).
  • Bedson HS , DuckworthMJ: Rabbit pox: an experimental study of the pathways of infection in rabbits.J. Pathol. Bacteriol.85 , 1–20 (1963).
  • Westwood JC , BoulterEA, BowenET, MaberHB: Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies.Br. J. Exp. Pathol.47(5) , 453–465 (1966).
  • Adams MM , RiceAD, MoyerRW: Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox.J. Virol.81(20) , 11084–11095 (2007).
  • Esteban DJ , BullerRM: Ectromelia virus: the causative agent of mousepox.J. Gen. Virol.86(Pt 10) , 2645–2659 (2005).
  • Xiao Y , Aldaz-CarrollL, OrtizAMet al. : A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.Vaccine25(7) , 1214–1224 (2007).
  • Zaucha GM , JahrlingPB, GeisbertTW, SwearengenJR, HensleyL: The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis).Lab. Invest.81(12) , 1581–1600 (2001).
  • MacNeill AL , MoldawerLL, MoyerRW: The role of the cowpox virus crmA gene during intratracheal and intradermal infection of C57BL/6 mice.Virology384(1) , 151–160 (2009).
  • Schultz DA , SagartzJE, HusoDL, BullerRM: Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virus.Virology383(1) , 86–92 (2009).
  • Tesh RB , WattsDM, SbranaE, SiirinM, PopovVL, XiaoSY: Experimental infection of ground squirrels (Spermophilus tridecemlineatus) with monkeypox virus.Emerg. Infect. Dis.10(9) , 1563–1567 (2004).
  • Xiao SY , SbranaE, WattsDM, SiirinM, da RosaAP, TeshRB: Experimental infection of prairie dogs with monkeypox virus.Emerg. Infect. Dis.11(4) , 539–545 (2005).
  • Hutson CL , OlsonVA, CarrollDSet al. : A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus.J. Gen. Virol.90(Pt 2) , 323–333 (2009).
  • Jahrling PB , HensleyLE, MartinezMJet al. : Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.Proc. Natl Acad. Sci. USA101(42) , 15196–15200 (2004).
  • Eckart RE , ShryEA, AtwoodJEet al. : Smallpox vaccination and ischemic coronary events in healthy adults.Vaccine25(50) , 8359–8364 (2007).
  • US FDA, HHS: New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final Rule. Fed. Regist. 67 , 37988–37998 (2002).
  • Liszewski MK , LeungMK, HauhartR, FangCJ, BertramP, AtkinsonJP: Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.J. Immunol.183(5) , 3150–3159 (2009).
  • Bell E , ShamimM, WhitbeckJC, SfyroeraG, LambrisJD, IsaacsSN: Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.Virology325(2) , 425–431 (2004).
  • Aldaz-Carroll L , XiaoY, WhitbeckJCet al. : Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6.J. Virol.81(15) , 8131–8139 (2007).
  • Walsh SR , GillisJ, PetersBet al. : Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques.Vaccine27(36) , 4990–5000 (2009).
  • Lehmann MH , KastenmullerW, KandemirJD, BrandtF, SuezerY, SutterG: Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression.J. Virol.83(6) , 2540–2552 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.